Cargando…
Diagnostic Efficacy and Therapeutic Decision-making Capacity of an Artificial Intelligence Platform for Childhood Cataracts in Eye Clinics: A Multicentre Randomized Controlled Trial
BACKGROUND: CC-Cruiser is an artificial intelligence (AI) platform developed for diagnosing childhood cataracts and providing risk stratification and treatment recommendations. The high accuracy of CC-Cruiser was previously validated using specific datasets. The objective of this study was to compar...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510889/ https://www.ncbi.nlm.nih.gov/pubmed/31143882 http://dx.doi.org/10.1016/j.eclinm.2019.03.001 |
_version_ | 1783417492387921920 |
---|---|
author | Lin, Haotian Li, Ruiyang Liu, Zhenzhen Chen, Jingjing Yang, Yahan Chen, Hui Lin, Zhuoling Lai, Weiyi Long, Erping Wu, Xiaohang Lin, Duoru Zhu, Yi Chen, Chuan Wu, Dongxuan Yu, Tongyong Cao, Qianzhong Li, Xiaoyan Li, Jing Li, Wangting Wang, Jinghui Yang, Mingmin Hu, Huiling Zhang, Li Yu, Yang Chen, Xuelan Hu, Jianmin Zhu, Ke Jiang, Shuhong Huang, Yalin Tan, Gang Huang, Jialing Lin, Xiaoming Zhang, Xinyu Luo, Lixia Liu, Yuhua Liu, Xialin Cheng, Bing Zheng, Danying Wu, Mingxing Chen, Weirong Liu, Yizhi |
author_facet | Lin, Haotian Li, Ruiyang Liu, Zhenzhen Chen, Jingjing Yang, Yahan Chen, Hui Lin, Zhuoling Lai, Weiyi Long, Erping Wu, Xiaohang Lin, Duoru Zhu, Yi Chen, Chuan Wu, Dongxuan Yu, Tongyong Cao, Qianzhong Li, Xiaoyan Li, Jing Li, Wangting Wang, Jinghui Yang, Mingmin Hu, Huiling Zhang, Li Yu, Yang Chen, Xuelan Hu, Jianmin Zhu, Ke Jiang, Shuhong Huang, Yalin Tan, Gang Huang, Jialing Lin, Xiaoming Zhang, Xinyu Luo, Lixia Liu, Yuhua Liu, Xialin Cheng, Bing Zheng, Danying Wu, Mingxing Chen, Weirong Liu, Yizhi |
author_sort | Lin, Haotian |
collection | PubMed |
description | BACKGROUND: CC-Cruiser is an artificial intelligence (AI) platform developed for diagnosing childhood cataracts and providing risk stratification and treatment recommendations. The high accuracy of CC-Cruiser was previously validated using specific datasets. The objective of this study was to compare the diagnostic efficacy and treatment decision-making capacity between CC-Cruiser and ophthalmologists in real-world clinical settings. METHODS: This multicentre randomized controlled trial was performed in five ophthalmic clinics in different areas across China. Pediatric patients (aged ≤ 14 years) without a definitive diagnosis of cataracts or history of previous eye surgery were randomized (1:1) to receive a diagnosis and treatment recommendation from either CC-Cruiser or senior consultants (with over 5 years of clinical experience in pediatric ophthalmology). The experts who provided a gold standard diagnosis, and the investigators who performed slit-lamp photography and data analysis were blinded to the group assignments. The primary outcome was the diagnostic performance for childhood cataracts with reference to cataract experts' standards. The secondary outcomes included the evaluation of disease severity and treatment determination, the time required for the diagnosis, and patient satisfaction, which was determined by the mean rating. This trial is registered with ClinicalTrials.gov (NCT03240848). FINDINGS: Between August 9, 2017 and May 25, 2018, 350 participants (700 eyes) were randomly assigned for diagnosis by CC-Cruiser (350 eyes) or senior consultants (350 eyes). The accuracies of cataract diagnosis and treatment determination were 87.4% and 70.8%, respectively, for CC-Cruiser, which were significantly lower than 99.1% and 96.7%, respectively, for senior consultants (p < 0.001, OR = 0.06 [95% CI 0.02 to 0.19]; and p < 0.001, OR = 0.08 [95% CI 0.03 to 0.25], respectively). The mean time for receiving a diagnosis from CC-Cruiser was 2.79 min, which was significantly less than 8.53 min for senior consultants (p < 0.001, mean difference 5.74 [95% CI 5.43 to 6.05]). The patients were satisfied with the overall medical service quality provided by CC-Cruiser, typically with its time-saving feature in cataract diagnosis. INTERPRETATION: CC-Cruiser exhibited less accurate performance comparing to senior consultants in diagnosing childhood cataracts and making treatment decisions. However, the medical service provided by CC-Cruiser was less time-consuming and achieved a high level of patient satisfaction. CC-Cruiser has the capacity to assist human doctors in clinical practice in its current state. FUNDING: National Key R&D Program of China (2018YFC0116500) and the Key Research Plan for the National Natural Science Foundation of China in Cultivation Project (91846109). |
format | Online Article Text |
id | pubmed-6510889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-65108892019-05-29 Diagnostic Efficacy and Therapeutic Decision-making Capacity of an Artificial Intelligence Platform for Childhood Cataracts in Eye Clinics: A Multicentre Randomized Controlled Trial Lin, Haotian Li, Ruiyang Liu, Zhenzhen Chen, Jingjing Yang, Yahan Chen, Hui Lin, Zhuoling Lai, Weiyi Long, Erping Wu, Xiaohang Lin, Duoru Zhu, Yi Chen, Chuan Wu, Dongxuan Yu, Tongyong Cao, Qianzhong Li, Xiaoyan Li, Jing Li, Wangting Wang, Jinghui Yang, Mingmin Hu, Huiling Zhang, Li Yu, Yang Chen, Xuelan Hu, Jianmin Zhu, Ke Jiang, Shuhong Huang, Yalin Tan, Gang Huang, Jialing Lin, Xiaoming Zhang, Xinyu Luo, Lixia Liu, Yuhua Liu, Xialin Cheng, Bing Zheng, Danying Wu, Mingxing Chen, Weirong Liu, Yizhi EClinicalMedicine Research Paper BACKGROUND: CC-Cruiser is an artificial intelligence (AI) platform developed for diagnosing childhood cataracts and providing risk stratification and treatment recommendations. The high accuracy of CC-Cruiser was previously validated using specific datasets. The objective of this study was to compare the diagnostic efficacy and treatment decision-making capacity between CC-Cruiser and ophthalmologists in real-world clinical settings. METHODS: This multicentre randomized controlled trial was performed in five ophthalmic clinics in different areas across China. Pediatric patients (aged ≤ 14 years) without a definitive diagnosis of cataracts or history of previous eye surgery were randomized (1:1) to receive a diagnosis and treatment recommendation from either CC-Cruiser or senior consultants (with over 5 years of clinical experience in pediatric ophthalmology). The experts who provided a gold standard diagnosis, and the investigators who performed slit-lamp photography and data analysis were blinded to the group assignments. The primary outcome was the diagnostic performance for childhood cataracts with reference to cataract experts' standards. The secondary outcomes included the evaluation of disease severity and treatment determination, the time required for the diagnosis, and patient satisfaction, which was determined by the mean rating. This trial is registered with ClinicalTrials.gov (NCT03240848). FINDINGS: Between August 9, 2017 and May 25, 2018, 350 participants (700 eyes) were randomly assigned for diagnosis by CC-Cruiser (350 eyes) or senior consultants (350 eyes). The accuracies of cataract diagnosis and treatment determination were 87.4% and 70.8%, respectively, for CC-Cruiser, which were significantly lower than 99.1% and 96.7%, respectively, for senior consultants (p < 0.001, OR = 0.06 [95% CI 0.02 to 0.19]; and p < 0.001, OR = 0.08 [95% CI 0.03 to 0.25], respectively). The mean time for receiving a diagnosis from CC-Cruiser was 2.79 min, which was significantly less than 8.53 min for senior consultants (p < 0.001, mean difference 5.74 [95% CI 5.43 to 6.05]). The patients were satisfied with the overall medical service quality provided by CC-Cruiser, typically with its time-saving feature in cataract diagnosis. INTERPRETATION: CC-Cruiser exhibited less accurate performance comparing to senior consultants in diagnosing childhood cataracts and making treatment decisions. However, the medical service provided by CC-Cruiser was less time-consuming and achieved a high level of patient satisfaction. CC-Cruiser has the capacity to assist human doctors in clinical practice in its current state. FUNDING: National Key R&D Program of China (2018YFC0116500) and the Key Research Plan for the National Natural Science Foundation of China in Cultivation Project (91846109). Elsevier 2019-03-17 /pmc/articles/PMC6510889/ /pubmed/31143882 http://dx.doi.org/10.1016/j.eclinm.2019.03.001 Text en © 2019 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Lin, Haotian Li, Ruiyang Liu, Zhenzhen Chen, Jingjing Yang, Yahan Chen, Hui Lin, Zhuoling Lai, Weiyi Long, Erping Wu, Xiaohang Lin, Duoru Zhu, Yi Chen, Chuan Wu, Dongxuan Yu, Tongyong Cao, Qianzhong Li, Xiaoyan Li, Jing Li, Wangting Wang, Jinghui Yang, Mingmin Hu, Huiling Zhang, Li Yu, Yang Chen, Xuelan Hu, Jianmin Zhu, Ke Jiang, Shuhong Huang, Yalin Tan, Gang Huang, Jialing Lin, Xiaoming Zhang, Xinyu Luo, Lixia Liu, Yuhua Liu, Xialin Cheng, Bing Zheng, Danying Wu, Mingxing Chen, Weirong Liu, Yizhi Diagnostic Efficacy and Therapeutic Decision-making Capacity of an Artificial Intelligence Platform for Childhood Cataracts in Eye Clinics: A Multicentre Randomized Controlled Trial |
title | Diagnostic Efficacy and Therapeutic Decision-making Capacity of an Artificial Intelligence Platform for Childhood Cataracts in Eye Clinics: A Multicentre Randomized Controlled Trial |
title_full | Diagnostic Efficacy and Therapeutic Decision-making Capacity of an Artificial Intelligence Platform for Childhood Cataracts in Eye Clinics: A Multicentre Randomized Controlled Trial |
title_fullStr | Diagnostic Efficacy and Therapeutic Decision-making Capacity of an Artificial Intelligence Platform for Childhood Cataracts in Eye Clinics: A Multicentre Randomized Controlled Trial |
title_full_unstemmed | Diagnostic Efficacy and Therapeutic Decision-making Capacity of an Artificial Intelligence Platform for Childhood Cataracts in Eye Clinics: A Multicentre Randomized Controlled Trial |
title_short | Diagnostic Efficacy and Therapeutic Decision-making Capacity of an Artificial Intelligence Platform for Childhood Cataracts in Eye Clinics: A Multicentre Randomized Controlled Trial |
title_sort | diagnostic efficacy and therapeutic decision-making capacity of an artificial intelligence platform for childhood cataracts in eye clinics: a multicentre randomized controlled trial |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510889/ https://www.ncbi.nlm.nih.gov/pubmed/31143882 http://dx.doi.org/10.1016/j.eclinm.2019.03.001 |
work_keys_str_mv | AT linhaotian diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT liruiyang diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT liuzhenzhen diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT chenjingjing diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT yangyahan diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT chenhui diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT linzhuoling diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT laiweiyi diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT longerping diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT wuxiaohang diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT linduoru diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT zhuyi diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT chenchuan diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT wudongxuan diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT yutongyong diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT caoqianzhong diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT lixiaoyan diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT lijing diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT liwangting diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT wangjinghui diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT yangmingmin diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT huhuiling diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT zhangli diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT yuyang diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT chenxuelan diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT hujianmin diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT zhuke diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT jiangshuhong diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT huangyalin diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT tangang diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT huangjialing diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT linxiaoming diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT zhangxinyu diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT luolixia diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT liuyuhua diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT liuxialin diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT chengbing diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT zhengdanying diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT wumingxing diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT chenweirong diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial AT liuyizhi diagnosticefficacyandtherapeuticdecisionmakingcapacityofanartificialintelligenceplatformforchildhoodcataractsineyeclinicsamulticentrerandomizedcontrolledtrial |